Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 million

• Immunovant posted a wider net loss of USD 153.2 million, or USD 0.75 a share, for the quarter ended June 30, 2026.
• R&D expense rose 40.91% to USD 142.6 million, due to IMVT-1402 trial activity including contract manufacturing costs, partly offset by lower batoclimab wind-down costs.
• G&A expense fell 31.92% to USD 17.7 million on lower personnel-related costs, professional fees, market research, and IT spending.
• Cash and cash equivalents totaled USD 797.8 million as of June 30, 2026, providing runway to a potential commercial launch of IMVT-1402 in Graves' disease.
• IMVT-1402 timelines stayed on track; CLE topline data are expected in 2H 2026, with GD and MG topline data anticipated in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001764013-26-000100), on August 06, 2026, and is solely responsible for the information contained therein.